XML 30 R23.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting

13. Segment Reporting

The Company operates and manages its business as one reportable and operating segment, which is the business of developing therapies for autoimmune and inflammatory diseases. The chief executive officer, who is the chief operating decision maker (“CODM”), reviews financial information on an aggregate basis for purposes of allocating resources, assessing performance and monitoring budget versus actuals. The CODM assesses performance based on net loss as reported on the statement of operations and comprehensive loss. Further, segment depreciation expense and segment asset additions are consistent with amounts reported within the statement of cash flows given the Company's operations are aggregated within a single reportable segment. All of the Company’s long-lived assets are located in the United States. Asset and other balance sheet information is not reported to the CODM.

The following table sets forth the Company’s summary of segment loss, including significant segment expenses for the three and six months ended June 30, 2025 and 2024 (in thousands):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

 

2025

 

 

 

2024

 

 

2025

 

 

 

2024

 

Research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

KYV-101 program

 

$

 

22,541

 

 

$

 

13,326

 

$

 

44,661

 

 

$

 

24,323

 

Other programs

 

 

 

986

 

 

 

 

512

 

 

 

1,498

 

 

 

 

3,140

 

Other research and development expenses(a)

 

 

 

12,289

 

 

 

 

13,483

 

 

 

27,090

 

 

 

 

22,334

 

General and administrative expenses(b)

 

 

 

8,594

 

 

 

 

6,114

 

 

 

18,569

 

 

 

 

12,996

 

Interest (income)

 

 

 

(2,364

)

 

 

 

(4,694

)

 

 

(5,189

)

 

 

 

(7,429

)

Interest expense and other expenses, net

 

 

 

35

 

 

 

 

62

 

 

 

87

 

 

 

 

132

 

Segment Loss and Net loss

 

$

 

42,081

 

 

$

 

28,803

 

$

 

86,716

 

 

$

 

55,496

 

 

(a) Primarily includes personnel costs, R&D professional services, unallocated CRO and CMO costs and allocated overhead and facilities expenses

(b) Primarily includes personnel costs, allocated overhead and facilities expenses, legal, IT, accounting and general and administrative expenses